Sequential intravesical gemcitabine and docetaxel for treatment-na ïve and previously treated intermediate-risk nonmuscle invasive bladder cancer

CONCLUSIONS: In this retrospective review of a heterogenous population of patients with intermediate-risk NMIBC, Gem/Doce was an effective and well-tolerated adjuvant therapy. Further prospective evaluation in this setting is needed.PMID:37442741 | DOI:10.1016/j.urolonc.2023.06.017

Source: Urologic Oncology - July 13, 2023 Category: Urology & Nephrology Authors: Ian M McElree Joanna Orzel Reid Stubbee Ryan L Steinberg Sarah L Mott Michael A O'Donnell Vignesh T Packiam Source Type: research